Notably, the efficacy of this combinatorial treatment in melanoma cells is not influenced by BRAF, NRAS or NF1 mutational status, opening the possibility of using these compounds to treat melanoma expressing high levels of SOX2 and GLI1 irrespectively to their mutational status. This evidence concerns the gene NRAS and melanoma.